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a b s t r a c t
Non-primate hepacivirus (NPHV) has been identiﬁed in dogs, horses, bats and wild rodents. The presence of
NPHV in dogs outside of the USA however is yet to be established. Here we describe for the ﬁrst time the
detection of NPHV in the UK dog population (described throughout the manuscript as CnNPHV). We examined
tissues collected from dogs housed in a rehoming kennel where respiratory disease was endemic. CnNPHV RNA
was detected in the tracheal tissues of 48/210 dogs by RT-PCR, and in the liver, lung and/or tracheal tissues of 12/
20 dogs. The presence of CnNPHV RNA, and its tropismwas conﬁrmed by in situ hybridisation. Histopathological
examination demonstrated a trend toward higher histopathological scores in CnNPHV RNA positive respiratory
tissues, although, this was not statistically signiﬁcant. Our ﬁndings broaden the geographic distribution and our
understanding of CnNPHV. Further evidence of CnNPHV replication in canids warrants investigation.
& 2015 Published by Elsevier Inc.
Introduction
Hepatitis C virus (HCV), the major causative agent of chronic
hepatitis, has a restricted host range. Whilst higher primates are
susceptible to experimental infection, natural infection has only
been detected in humans (Choo et al., 1994, 1989; Kuo et al., 1989;
Saito et al., 1990). An estimated 3% of the world population is
chronically infected with HCV, which is causally linked to cirrhosis,
liver failure and hepatocellular carcinoma (Shimotohno, 1995). The
lack of a non-primate animal model and a limited in vitro cultiva-
tion system for HCV make vaccine and drug development for the
virus challenging (Fried et al., 2002).
The hepacivirus genus, one of the four genera in the family
Flaviviridae, comprises of HCV and GBV-B (Stapleton et al., 2011). GBV-
Bwas isolated during the laboratory passage of human plasma (obtained
from an individual with unexplained acute hepatitis) through Tamarins
and other new world monkey species, but was never again recovered
from a human sample (Stapleton et al., 2011). The natural host of GBV-B
has thus remained elusive (Bukh et al., 1999, 2001; Nam et al., 2004;
Stapleton et al., 2011). Recently, Kapoor et al. (2011) described a novel
viruswith considerable genomic similarity to HCV in respiratory samples
of domestic dogs and tentatively named it canine hepacivirus. More
recently it has also been detected in horse serum (Burbelo et al., 2012;
Lyons et al., 2012), and both viruses are currently grouped as non-
primate hepacivirus (NPHV). Comparative phylogenetic analysis con-
ﬁrmed NPHV as the closest genetic relative of HCV to date (Burbelo et al.,
2012; Kapoor et al., 2011; Lyons et al., 2012). Whether HCV has
originated from animal species remains unclear. However, sustained
contact between humans and other species increases the likelihood of
the emergence of a virus adapted to infect and cross the species barrier.
The identiﬁcation of another virus related to HCV raises the
possibility that these viruses might be more widespread in mammals
than previously thought. More recently, novel hepacivirus has been
detected in bats and wild rodents (Drexler et al., 2013; Quan et al.,
2013). However, the detection of viral sequences from single tissue or
serum samples leaves unanswered questions about the prevalence and
tropism of the virus, and its association with disease. In this investiga-
tion we examined tissue samples from 210 dogs for the presence of
CnNPHV RNA. Due to its potential relevance for hepatitis, and its
previously reported detection in respiratory tissues, respiratory and
hepatic tissues from a further 20 dogs were examined for the presence
of CnNPHV. Clinical respiratory scores and a detailed histological
examination of these tissues were undertaken to investigate any
association between the presence of CnNPHV, clinical disease and
histopathological changes. This is the ﬁrst study to report the detection
of CnNPHV in dogs outside of the USA and the ﬁrst detailed investiga-
tion into the pathogenesis of natural cases of CnNPHV infection in dogs.
Results
Viral RNA sample screening
Population [A]
Tracheal samples were screened for the presence of CnNPHV
using the NS3 degenerate nested PCR. Forty eight of the 210
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samples (22.9%; 95% CI: 17.4–29.1%) had amplicons between the
expected size of 300–500 bp and were conﬁrmed as CnNPHV by
sequence analysis (Table 1). The highest proportion of CnNPHV-
positive dogs were detected among dogs sampled in 1999 (37.1%)
compared to 21.4% in 2000 and 18.7% in 2001, but this difference
was not signiﬁcant (p¼0.080).
Population [B]
To explore the potential of a dual respiratory and hepatic
tropism of CnNPHV in UK dogs, tracheal, lung and liver tissues
were screened for the presence of viral RNA by PCR using NS3-
speciﬁc primers. Sequence analysis conﬁrmed the identity of NS3
in the trachea of 7 dogs (35%), in the lung of 3 dogs (15%) and in
the liver of 8 dogs (40%) from a total of 20 dogs (Table 2). In 6 dogs,
viral RNA was present in both hepatic and respiratory tissues (3
dogs: lung and liver, 3 dogs: trachea and liver). In 6 dogs viral RNA
was detected in single tissues (4 dogs: trachea only, 2 dogs: liver
only). In the remaining 8 dogs, all three tissues were negative for
CnNPHV RNA.
Sequence analysis
To determine the relatedness between CnNPHV variants from
this study with those of previously published sequences, NS3
sequence (165 nt fragments) obtained from 4 dogs in population
[A] and all CnNPHV RNA-positive tissues from the 12 dogs in
population [B] (n¼18) were compared to published sequences
from USA, Germany, Brazil and UK. Our canine NS3 variants
had overall a relatively higher nucleotide identity to canine
(89.6–100% nt and 90.9–100% a.a.) and equine strains (95.7–100%
nt and 89–100% a.a.) from the USA than to that of equine strains
from the UK, Germany and Brazil (Table 3).
To further assess the relatedness of our variants to published
sequences in regions other than NS3, one E1/E2 tracheal variant (42-T)
and two 50UTR tracheal variants (5-T and 12-T) from population [A]
were analysed. Alignment of 42-T E1/E2 (962 nt) to that of the
published NPHV sequences revealed a nucleotide identity of 87.8%
(92.4% a.a.) to the only published canine sequence (Accession no.
JF744991) and 81.3–89.1% (88.5–94.4% a.a.) to 5 equine sequences
(Accession no. JQ434001, JQ434003, JQ434004, JX948116 and KF17-
7391). 42-T had 24 amino acid substitutions relative to that of the
prototype canine isolate, and 18–38 amino acid substitutions relative
to that of equine strains. Upon alignment of the 50UTR, 5-T and 12-T
shared 98.4% nucleotide identity. When 5-T and 12-T were compared
to the published 50UTR sequence, they had 94.5–100% nucleotide
identity with the canine (AAK-2011) and equine NPHV sequences
(Accession no. JF744991, JQ434001-JQ434008, JX948116, JX948117,
JX948120, KJ472766 and KF177391).
Phylogenetic analysis of the NS3 sequence (165 nt fragment)
revealed that the canine variants from this study grouped (Fig. 1A)
most closely to the USA canine strains (Accession no. JF744991-96 and
JQ181558) and one USA equine isolate (Accession no. JQ434001).
Similarly, the 50UTR of 5T and 12T grouped with the only available
canine sequence for this region (Accession no. AF744991) and the
same USA equine isolate (Accession no. JQ434001) (Fig. 1C). In
contrast, E1/E2 of 42-T grouped most closely with two different
equine strains (JQ434003 and JQ434004) (Fig. 1B).
In situ localisation of viral RNA in canine trachea, lung and liver
To further conﬁrm the CnNPHV RNA positive results obtained
by RT-PCR, RNA was probed by in situ hybridisation (ISH) in liver,
lung and tracheal tissues of CnNPHV RNA-positive and negative
dogs (Fig. 2). Foci of viral RNA were located in the cytoplasm of
ciliated epithelial cells within the trachea and alveolar epithelium
of the lungs in a CnNPHV RNA-positive dog while no staining was
observed in a CnNPHV RNA-negative dog. ISH in the liver revealed
dispersed as well as focal infection predominantly in the cyto-
plasm of hepatocytes (Fig. 2). GAPDH staining was evident in all
tissues tested (results not shown).
Assessment of the clinical respiratory signs in CnNPHV RNA-positive
dogs
To examine the association between the presence of CnNPHV
RNA and respiratory disease in dogs, the clinical respiratory scores
were evaluated.
Population [A]
Overall 70.8% (n¼34/48; 95% CI: 55.9–83.0%) of CnNPHV RNA-
positive dogs had signs of clinical respiratory disease compared to
63.0% (n¼102/162; 95% CI: 54.7–70.0%) of CnNPHV RNA-negative
dogs (Table 1), although this was not signiﬁcantly different
(p¼0.118). The biggest difference was seen in dogs with a
respiratory score of 3, where 50.0% (n¼24/48; 95% CI: 35.2–
64.8%) of CnNPHV RNA-positive dogs and 31.5% (n¼51/162; 95%
CI: 24.4–39.2%) of CnNPHV RNA-negative dogs had a cough and
nasal discharge. Clinical respiratory scores of 4 and 5 were
recorded in only a small number of CnNPHV RNA-positive dogs
(n¼3 and n¼2).
Population [B]
Upon examination of the clinical respiratory score of the 20
dogs, one CnNPHV RNA-positive dog had a mild cough (score 2)
and 3 CnNPHV RNA-positive dogs had a cough and nasal discharge
(score 3). The remaining 8 CnNPHV RNA-positive dogs had no
obvious respiratory disease (score 1) (one dog had no available
score). None of the dogs that were CnNPHV RNA-negative had
signs of respiratory disease with the exception of one dog which
had a cough and nasal discharge (Table 2).
Table 1
Population A: the detection of CnNPHV RNA by measured variable.
Measured variable CnNPHV PCR Totala
Positive Negative
Number % Number % Number %
Year 1999 13 27.1 22 13.6 35 16.7
2000 18 37.5 66 40.7 84 40.0
2001 17 35.4 74 45.7 91 43.3
Length of stay 1–7 5 10.4 13 8 18 8.6
8–14 25 52.1 83 51.2 108 51.4
15–21 6 12.5 26 16.0 32 15.2
22–28 5 10.4 17 10.5 22 10.5
428 7 14.6 23 14.2 30 14.3
Clinical score 1 14 29.2 60 37.0 74 35.2
2 5 10.4 32 19.8 37 17.6
3 24 50.0 51 31.5 75 35.7
4 3 6.3 6 3.7 9 4.3
5 2 4.2 13 8.0 15 7.2
Histology score 0 3 6.3 15 9.3 18 8.6
1 30 62.5 87 53.7 117 55.7
2 10 20.8 42 25.9 52 24.7
3 5 10.4 18 11.1 23 11.0
Co infection Y 20 41.7 61 37.7 81 38.6
N 28 58.3 101 62.3 129 61.4
Total 48 100 162 100 210 100
a The total % represents the proportion of dogs in the measured variable out of
the total 210 dogs.
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Assessment of CnNPHV RNA detection in relation to length of stay in
the kennel
The association between the detection of CnNPHV RNA and
length of stay in the kennel was examined.
Population [A]
Overall there was no signiﬁcant association between the
detection of CnNPHV RNA and the length of stay in the kennel
(p¼0.967). Of the 48 CnNPHV RNA-positive samples 10.4% (n¼5/
48, 95% CI:3.5–22.7%) were detected in dogs resident in the kennel
for 1–7 days. This increased to 52.1% (n¼25/48; 95% CI: 37.2–
66.7%) for 8–14 days, followed by a decline to 12.5% (n¼6/48; 95%
CI: 4.7–25.2%) for 15–21 days and 10.4% (n¼5/48; 95% CI: 3.5–
22.7%) for 22–28 days (Table 1).
Population [B]
Detection of CnNPHV RNA in population [B] followed a similar
trend to population [A], with regard to viral detection and length
of stay in the kennel.
Table 3
The percentage of nucleotides and amino acids differences in NS3 between CnNPHV variants in UK dogs identiﬁed in this study and equine reference strains from different
geographical locations.
Species USA UK Germany Brazil
Accession numbers JQ434001, JQ434003 and JQ434006, JX948118 and JX948121 KC411810 and KC411811 KJ469459 and KJ469466
Tissue types Nucleotides Amino acids Nucleotides Amino acids Nucleotides Amino acids Nucleotides Amino acids
Trachea 89.6–100 90.9–100 83.6–89.6 89.0–98.1 87.8–90.9 89.0–98.1 83.6–89.6 89.0–100
Lung 91.5–100 96.3–100 85.4–87.8 96.3–98.1 89.6–90.9 96.3–98.1 85.4–89.6 96.3–100
Liver 90.9–100 94.5–100 85.4–87.8 94.5–98.1 89.0–90.9 94.5–98.1 84.8–89.6 94.5–98.1
Overall 89.6–100 90.9–100 83.6–89.6 89.0–98.1 87.8–90.9 89.0–98.1 83.6–89.6 89.0–100
Table 2
Population B: the detection of CnNPHV RNA by measured variable.
Measured variable CnNPHV PCR Total
Positive Negative
Number % Number % Number %
Clinical score 1 7 63.6 6 85.7 13 65.0
2 1 9.1 0 0.0 1 5.0
3 3 27.3 1 14.3 4 20.0
4 0 0.0 0 0.0 0 0.0
5 0 0.0 0 0.0 0 0.0
Missing data 1 9.1 1 14.3 2 10.0
Total 12 100a 8 100a 20 100b
Co-infection Y 6 2 8 40.0
N 6 6 12 60.0
Total 12 60.0b 8 40.0b 20 100.0b
Trachea histology score 0 0 2 2
1 1 5 6
2 2 0 2
3 2 1 3
4 2 3 5
Not examined 0 2 2
Total 7 35.0b 13 65.0b 20 100.0b
Cilia (Trachea) histology score 0 0 2 2
1 0 1 1
2 2 3 5
3 2 1 3
4 3 4 7
Not examined 0 2 2
Total 7 35.0b 13 65.0b 20 100.0b
Lung histology score 0 0 3 3
1 1 5 6
2 0 8 8
3 1 0 1
4 1 1 2
Not examined 0 0 0
Total 3 15.0b 17 85.0b 20 100.0b
Liver histology score 0 4 4 8
1 1 4 5
2 2 2 4
3 0 1 1
4 0 0 0
Not examined 1 1 2
Total 8 40.0b 12 60.0b 20 100.0b
a The total % represents the proportion of dogs by CnNPHV PCR results.
b The total % represents the proportion of the total 20 dogs examined.
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Fig. 1. Phylogenetics analysis by the Maximum Likelihood method of (A) NS3, (B) E1/E2 and (C) 50UTR of non-primate hepacivirus sequence ampliﬁed in this study. The
evolutionary history was inferred by using the maximum Likelihood method of the MEGA 6 programme based on the Kimura- 2 Model for NS3, Hasegawa–Kishino–Yano
model for E1/E2 and Tamura–Nei model for 50UTR. Initial tree(s) for the heuristic search were obtained automatically by applying Neighbor–Join and BioNJ algorithms to a
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, where the topology with superior log likelihood of each tree was selected.
The numbers at the nodes (bootstrap values) indicate the frequencies of occurrence for 500 replicate trees. (ο) Published canine hepacivirus sequence, (□) published equine
hepacivirus sequence, (Δ) published hepacivirus sequence in bat and () M62321/HCV subtype 1a was used as an outgroup. (●) Canine hepaciviruses sequenced in this study
are indicated. Tree scales represent branch length measured in the number of substitution per site.
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Co-infection with other respiratory viruses in the CnNPHV RNA-
positive dogs
The incidence of co-infection with important CIRD viruses
(CRCoV, CnPnV and CHV) was examined. CDV, CPIV and CAdV
(1þ2) were not included in this analysis as the dogs were
vaccinated against these agents upon entry to the kennel.
Population [A]
Out of the 48 CnNPHV RNA-positive dogs 41.7% (n¼20) had
evidence of co-infection with one or more CIRD viruses (Table 1).
Of these 20 dogs 14 (70%) had respiratory disease (respiratory
score 2–5). Of the 28 dogs without co- infection 20 (71.4%) had
respiratory disease. Overall, there was no signiﬁcance difference
between the respiratory score of dogs with or without co-infection
(p¼0.367).
Population [B]
None of the 20 dogs had evidence of co-infection with CnPnV.
Of the 12 dogs screened positive for CnNPHV RNA, 5 dogs were
positive for CRCoV and one dog was positive for canine herpes
virus. The remaining 6 dogs had no evidence of co-infection with
any of the respiratory viruses listed above. Of the six dogs with no
evidence of co-infection, 50.0% (n¼3) were manifested by mild
cough (score 2) and cough associated with nasal discharge
(score 3).
Histopathological examination of the CnNPHV RNA-positive dogs
To evaluate the relationship between CnNPHV RNA detection
and histopathological changes in dogs, formalin-ﬁxed parafﬁn
embedded tissue sections of populations [A] and [B] were exam-
ined histologically.
Trachea
Lung
Liver
Fig. 2. In situ hybridisation of CnNPHV RNA in canine trachea, lung and liver. Slides A, B, C are CnNPHV RNA-positive dogs and slides D, E, F are from an uninfected dog. Bright
red dots indicate probe bound to CnNPHV genomic RNA as indicated by arrows. Nuclei are stained blue by haematoxylin.
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Population [A]
Of the 48 CnNPHV RNA-positive dogs, 62.5% (n¼30) had an
overall histopathological score of 1 compared to 53.7% (n¼87) of
CnNPHV RNA-negative dogs (Table 1). Histopathological scores of
2 and 3 were recorded for 20.8% (n¼10) and 10.4% (n¼5) of
CnNPHV RNA-positive dogs respectively, compared with 25.9%
(n¼42) and 11.1% (n¼18) of CnNPHV RNA-negative dogs.
Overall there was no signiﬁcant association between the
histopathological score of respiratory tissues and the presence of
CnNPHV RNA in this population (p¼0.727). However dogs with
histopathological scores of 1–3 were more likely to be positive for
CnNPHV RNA than dogs with a histopathological score of 0 (OR:
2.1, 1.7 and 1.4 respectively).
Twenty eight out of the 48 dogs (58.3%) dogs were positive for
CnNPHV RNA alone, with no other respiratory viruses detected. In
this sub-population there was no signiﬁcant association between
CnNPHV RNA detection and respiratory histopathology (p¼0.769).
Population [B]
Sections of trachea, lung and liver were examined.
Trachea. 3/20 dogs (15.0%) were positive for only CnNPHV RNA in the
trachea, with no other respiratory viruses detected. Histopathological
scores for 3 dogs ranged from 2 to 4 with a mean of 3. The same dogs
had a mean cilia score of 3. Histopathological changes were principally
various degrees of lymphoplasmacytic tracheitis with more occasional
involvement of neutrophils. In 3/20 (15.0%) CnNPHV RNA-negative
dogs, also negative for other respiratory viruses, the histopathological
and cilia scores were 0, 0 , 1 and 0, 1, 2 respectively.
Lung. 1/20 dogs (5.0%) were positive for only CnNPHV RNA in the
lung, with no other respiratory viruses detected, and had a
histopathological score of 3. Histopathological changes included mild
to occasionally moderate alveolar histiocytosis and mild alveolar wall
thickening, suggestive of early interstitial pneumonia. In 3/20 (15.0%)
CnNPHV-negative dogs, also negative for other respiratory viruses, the
histopathological scores were 1, 1 and 2 with a mean of 1.33.
Liver. 8/20 dogs (40.0%) were positive for CnNPHV RNA in the
liver. Histopathological scores were available for 7/8 dogs and
ranged from 0 to 2 with a mean of 0.71. Histopathological changes
detected in these dogs were relatively non-speciﬁc and included
mild to moderate sinusoidal congestion and in most cases clear to
ﬁnely vacuolated zonal hepatocyte cytoplasmic swelling (hydropic
degeneration), consistent with mild sublethal cell injury. In 8/20
(40.0%) CnNPHV RNA-negative dogs, histopathological scores were
available for 7/8 and ranged from 0 to 3 with a mean of 1.1.
Discussion
CnNPHV was ﬁrst detected in nasal swabs collected from dogs
from a number of different respiratory disease outbreaks in the
USA, and in the liver of dogs which died from unexplained
gastroenteritis (Kapoor et al., 2011). Subsequent efforts to ﬁnd
CnNPHV in serum, lung, liver or spleen of dogs undergoing
investigations for respiratory disease or idiopathic hepatitis were
unsuccessful (Bexﬁeld et al., 2014; Drexler et al., 2013; Lyons et al.,
2012). Here, we report for the ﬁrst time the detection of CnNPHV
in the respiratory and hepatic tissues of UK dogs.
We screened the tracheal tissues of 210 dogs (population [A])
for CnNPHV RNA of which 48 dogs (22.9%) were positive for the
virus by RT-PCR and conﬁrmed by DNA sequencing.
To explore the previously reported dual respiratory and hepatic
tropism of CnNPHV (Kapoor et al., 2011), we examined also the
trachea, lung and liver of 20 dogs (population [B]). CnNPHV RNA
was detected in 12 of the dogs (60%) and in all three tissue types
(lung of 3 dogs, trachea of 7 dogs and liver of 8 dogs) by RT-PCR
and DNA sequencing. The presence of the virus within the tissues
was further conﬁrmed by in situ hybridisation, where foci of viral
RNA were detected only in the cytoplasm of ciliated epithelial cells
in the trachea, alveolar epithelium in the lung and hepatocytes in
CnNPHV RT-PCR positive dog.
To examine the genetic relatedness between variants detected
in our study and that of published strains we aimed to sequence
the 50 UTR and E1/E2 regions of the CnNPHV genome, in addition
to the NS3 domain. The conserved 50UTR is important for virus
replication/translation and has been used for HCV genotyping
(Pestova et al., 1998; Simmonds, 2004). The E1/E2 envelope genes
facilitate virus entry into host cells and display the most diverse
sequences among HCV genomes (Hijikata et al., 1991; Kato et al.,
1992; Weiner et al., 1991). Analysis of the NS3 sequence gener-
ated from some of the variants in this study, although based on a
short fragment (165 nt), showed that differences existed between
the strains detected in this study and with those previously
published, but was most similar to the published canine strain
AAK-2011 from the USA (Accession no. JF744991) and the equine
strain (NZP-1). NZP-1 was previously shown to share high degree
of nucleotide identity with the canine strain AAK-2011 (Burbelo
et al., 2012; Kapoor et al., 2011; Lyons et al., 2014,2012). Likewise
50UTR obtained from two tracheal variants showed substantial
nucleotides similarity to canine and equines published
sequences. E1/E2 sequence obtained from one tracheal variant
(42-T) showed the least similarity to canine and equine published
sequence compared to NS3 and 50UTR reﬂecting the heterogene-
ity of E1/E2 genes among HCV genome (Hijikata et al., 1991; Kato
et al., 1992; Weiner et al., 1991). Sequence analysis of E1/E2 and
50UTR from more samples would be advantageous. Since the
main focus of this study was to establish the presence of CnNPHV
in the UK canine population further sequence analysis of E1/E2
from more samples was not perused. A standalone dedicated
study focused on genomic variation is required. What this study
does highlight however, even with the limited E1/E2 sequence
obtained, is the high degree of diversity in E1/E2 between
CnNPHV genomes, indicating the requirement for more broadly
reactive primers to successfully target this genomic region from
multiple variants.
The NS3, 50UTR and E1/E2 variants identiﬁed in this study
conﬁrmed the results of RT-PCR and showed a degree of diversity
from that of published sequence, particularly those of equine
origin. However full genome sequences are required to accurately
postulate sequence diversity.
Our study conﬁrms the ﬁndings initially reported (Kapoor et al.,
2011) by demonstrating the presence of CnNPHV-RNA in canine
tissues, and extends their ﬁndings by demonstrating for the ﬁrst time
the presence of CnNPHV RNA in lower respiratory tract. The failure of
other studies to ﬁnd evidence of CnNPHV in the UK dogs (Lyons et al.,
2012) may be due to differences in the dog population screened. In
this study, kennelled dogs were targeted since infectious agents are
often more likely to be present within a kennel environment due to
crowded conditions, which facilitates transmission, and/or the often
increased susceptibility of animals due to malnourishment, underlying
disease or immunosuppression.
Respiratory disease in particular spreads quickly among ken-
nelled dogs, and studies have shown that many of the associated
pathogens are readily transmitted during the ﬁrst two weeks of
the dogs stay (Chalker et al., 2004; Erles et al., 2004; Mitchell et al.,
2013b). Although not statistically signiﬁcant (p¼0.967), CnNPHV
RNA was most frequently detected in dogs resident in the kennel
for 8–14 days in population [A] (Table 1). The overall higher
detection rate (60%) of CnNPHV RNA in population [B] could
L.M.R. El-Attar et al. / Virology 484 (2015) 93–10298
therefore be a result of biased sampling in which a majority of
samples (41.7%) were collected from dogs resident in the kennel
between 8 and 14 days.
This suggests that CnNPHV may be transmitted to dogs during the
1st and 2nd weeks of entering the kennel as has been shown for other
canine viruses in this kennelled population (Erles et al., 2003; Mitchell
et al., 2013b). To further investigate this would require comprehensive
serological survey using paired samples, and daily swabbing of dogs
following entry to the kennel for viral detection.
CnNPHV transmission within the same species and across
species has been previously reported (Burbelo et al., 2012; Lyons
et al., 2014). In one study the CnNPHV isolate detected in a
commercial horse serum pool NZP-1 was almost identical to that
from a dog, providing evidence for the ability of NPHV to cross
species (Burbelo et al., 2012). Whilst in a recent study by Lyons
et al. (2014), all horses that were stable mates of a CnNPHV
viraemic horse seroconverted as did a dog on the same farm
(Lyons et al., 2014).
Due to the presence of CnNPHV RNA in tissues from both the
upper and lower airways of dogs the clinical respiratory signs were
analysed against the CnNPHV RT-PCR result to explore the possi-
bility of an association between CnNPHV and respiratory disease.
Overall no signiﬁcant association was detected (p¼0.118). How-
ever there was a general trend toward a higher incidence of
respiratory disease in CnNPHV RNA-positive dogs (70.8%) when
compared to hepacivirus negative dogs (63.0%) in population [A].
The lower percentage of dogs with signs of respiratory disease in
population [B] compared to population [A] may be biased by the
small number of dogs.
Given this ﬁnding it is likely that the disease observed was
primarily caused by other pathogens. Indeed canine infectious
respiratory disease (CIRD) is a multifactorial disease involving a
number of infectious viral agents (Priestnall et al., 2014). Whilst all
the dogs in this study were vaccinated on the day of entry against
CPIV, CDV, CAdV-2, other CIRD pathogens (CRCoV, CHV, CnPnV)
have previously been associated with the onset and persistence of
CIRD in these dog populations (Erles et al., 2004, 2003; Mitchell
et al., 2013b). In examining the dogs for co-infection with these
viruses, we did not observe any signiﬁcant difference in the
severity of respiratory disease between CnNPHV RNA-positive
dogs with and without viral co-infection. Previously reported but
not examined within the context of co-infections in this study is
role of bacteria in the pathogenesis of CIRD. Previously Bordetella
bronchiseptica, Mycoplasma cynos and Streptococcus zooepidemicus
have also been associated with increased severity and persistence
of disease within this cohort (Chalker et al., 2003a, 2003b, 2004).
Histopathological examination of the lung and tracheal tissues
does not reveal a statistically signiﬁcant association between the
presence of CnNPHV and the histopathological changes observed.
However, given the high incidence of co-infection with multiple
respiratory viruses this association might be harder to prove. To
address this, the number of dogs positive solely with CnNPHV RNA
was assessed and, although not statistically signiﬁcant, both
histopathological scores in trachea and lung and cilia scores in
trachea were higher in CnNPHV RNA-positive versus CnNPHV RNA-
negative dogs (population [B]). The typical histopathological
changes observed within these latter dogs, including mild to
moderate lymphoplasmacytic tracheitis and lesions typical of early
interstitial pneumonia are those that would be expected with a
viral respiratory infection.
The complexity of CIRD therefore makes it difﬁcult to tease out
the contributions individual pathogens make, without much larger
clinical studies, or the use of experimental challenge models.
Within the context of a multifactorial disease these ﬁndings
therefore cannot exclude the possibility of a role for CnNPHV in
CIRD, and further work is required to fully assess this.
The high prevalence of CnNPHV RNA in 8/20 liver supports the
hypothesis that CnNPHV may have a hepatic tropism like HCV.
However the fact that CnNPHV RNA can also be detected from
respiratory tissue indicates a wider tissue tropism. Although the liver
is considered to be the primary target for HCV, extrahepatic manifes-
tations are well recognised among patients with chronic HCV infection
(Hadziyannis, 1997; Latt et al., 2012; Zignego et al., 2012). For instance,
HCV RNA has been detected in saliva of infected patients (Pastore
et al., 2006; Ruggieri et al., 1996). Whether or not HCV infection is
associated with respiratory disease in humans remain unknown. Most
clinical cases of HCV infection go unrecognised until an initial
diagnosis is made during the late stages of chronic liver disease, and
therefore data relating to the extrahepatic tropism of the virus during
the early phase of infection is limited.
Histopathological changes in the liver were roughly equivalent in
both CnNPHV RNA-positive and negative dogs and thus, although the
virus is present, there is no deﬁnitive association with morphological
changes in this small population [B]. The 7 available histopathological
scores of the CnNPHV RNA-positive liver samples had a mean of 0.71
indicative of mild changes. Assuming these dogs were infected with
CnNPHV, the liver samples would have been collected at a relatively
early stage of viral infection and thus given that in HCV, hepatic
lesions are most severe in late-stage chronic infections, we cannot
exclude the possibility that more chronic lesions, such as ﬁbrosis or
biliary hyperplasia may have developed in these dogs. This latter
theory should prompt awider investigation into the role of CnNPHV in
chronic hepatitis, a common and largely idiopathic clinical problem in
dogs. Indeed morphological changes in the liver are often preceded by
functional changes, such as elevations in hepatocellular enzymes
which were not analysed in this retrospective study. Interestingly
two recent studies in UK and Netherlands reported the absence of
CnNPHV in liver samples from dogs with chronic and idiopathic
hepatitis (Bexﬁeld et al., 2014; Drexler et al., 2013). These studies
however may not be representative of the global picture.
The histopathological changes observed with chronic HCV
infection are characterised by portal inﬂammation including
cholangiohepatitis and periportal injury in the form of piecemeal
necrosis of hepatocytes and ﬁbrosis (Scheuer et al., 1992) where
the latter is the progressive component of the disease leading
eventually to liver cirrhosis. However in HCV infection, there is a
disparity between the observed numbers of patients with clinical
evidence of cirrhosis as compared to the proportion of patients
with chronic HCV in whom histological evidence of cirrhosis
develops due to the indolent nature of HCV-induced cirrhosis
(Sanchez-Tapias et al., 1990). Additionally, HCV replication occurs
in the absence of obvious liver damage during the ﬁrst few months
after infection (Shimizu and Purcell, 1989). If CnNPHV has a similar
very slow disease progression and the fact that canine species has
shorter life span than human, the expected scenario would be that
most CnNPHV-infected dogs would probably die before showing
any evidence of liver damage. Nevertheless the lack of evidence of
histological abnormalities in liver tissues may also be explained by
the possibility that these dogs have recently acquired the infection
whilst in the kennel. Additionally the age of these dogs ranged
from 1 to 4 years old, targeting older dogs would be a useful
further strategy to demonstrate any evidence of liver injury.
In conclusion, CnNPHV has been detected in two populations of
dogs. Further analysis demonstrated CnNPHV RNA present within
liver, lung and tracheal tissues. To our knowledge this is the ﬁrst in
depth investigation of CnNPHV in the UK dogs. In our study of
relatively young dogs (1–4 years), we have observed the highest
levels of infection in the liver of these animals but, as yet, little
evident pathology. It would be valuable to examine older dogs,
particularly those with liver disorders to assess whether there is
any signiﬁcant association between CnNPHV and hepatitis. As yet
the source of CnNPHV in dogs is unknown. It is possible the virus
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detected in this study was introduced to these dogs from either
contact with other dogs, wildlife or other sources such as vaccine
contaminated with animal serum or ingestion of food. Further
investigation to examine whether or not CnNPHV is replicating in
these dogs is warranted, and a further evolutionary analysis of
whole viral genome is required to investigate the natural history of
these novel viruses.
Materials and methods
Study population
(i) Population deﬁnition
Samples used in this study were obtained from dogs residing in
a well-established canine rehoming centre in London, UK with a
history of endemic respiratory disease. The dogs were grouped as
follows: Population [A]: 210 dogs housed in the kennel between
1999 and 2001 and population [B]: 20 dogs housed in the kennel
in 2004.
All dogs were vaccinated upon entry into the kennel with
KAVAK DA2 PiP69 (Fort Dodge), a live attenuated vaccine for
distemper virus (CDV), canine adenovirus type 2 (CAdV-2), canine
parainﬂuenza virus (CPIV), and canine parvovirus (CPV), and a
killed leptospirosis vaccine (Fort Dodge).
(ii) Data collection
The kennel admission history, vaccination and clinical respira-
tory scores of the two populations were recorded as described
previously (Erles et al., 2003; Mitchell et al., 2013b). The health
status of each dog was assessed twice a day by a veterinary
clinician and graded on the day of euthanasia as follows: (1) no
respiratory signs, (2) mild cough, (3) cough and nasal discharge,
(4) cough, nasal discharge, and inappetence, (5) evidence of
bronchopneumonia.
(iii) Sample collection
Tissue samples were collected at post-mortem examination
with informed consent where dogs were euthanised for welfare
and ethical reasons unrelated to this study, ranging from beha-
vioural problems to signs of severe respiratory disease. Multiple
respiratory tissues samples were collected in duplicate where one
section was frozen at 70 1C for virological analysis and the other
ﬁxed in neutral buffered formalin (NBF) prior to histological
preparation.
Sample analysis
Tracheal samples from population [A] and tracheal, lung and
liver samples from population [B] were analysed for the presence
of CnNPHV by RT-PCR and assessed for histological changes.
(i) RNA extraction, cDNA synthesis and PCR
RNA was extracted from tracheal, lung and liver tissues using
the Qiagen RNeasy tissue puriﬁcation kit according to the manu-
facturer's instructions. Approximately 25–30 mg of homogenised
tissue was used and the RNA was eluted in 40 ml of nuclease-free
water. Total RNA was reverse transcribed into cDNA using random
hexamer primers and superscript III reverse transcriptase (Life
Technology) as described by the manufacturers.
Detection of GAPDH by PCR. To validate cDNA synthesis, all samples
were tested for the presence of the house keeping gene
glyceraldhyde-3-phosphate dehydrogenase (GAPDH) by PCR as
described by Grone et al. (1996) using GoTaqs Flexi DNA
Polymerase kit (Promega) following the manufacturer's protocol.
Detection of CnNPHV by NS3 PCR. Tracheal samples from
population [A] were screened for CnNPHV by nested PCR using
previously described degenerate primers targeting the CnNPHV
NS3 gene (Burbelo et al., 2012; Kapoor et al., 2011). Amplicons of
300–500 bp were generated using Hotstart Taq polymerase
(Qiagen). The primary round underwent an initial denaturation
at 95 1C for 7 min followed by 10 cycles of [95 1C for 40 s, 60 1C
(0.5 1C/cycle) for 45 s and 72 1C for 1 min] and 30 cycles of [95 1C
for 30 s, 54 1C for 40 s and 72 1C for 1 min] with ﬁnal elongation
step at 72 1C for 10 min. The secondary round underwent the same
cycling parameters as the primary round except for the annealing
temperature which was 62 1C for 10 cycles followed by 58 1C for 30
cycles. NPHV positive control plasmid DNA provided by Kapoor
et al. (2011) was included in each run.
Tracheal, lung and liver samples from population [B] were
screened for CnNPHV using a single round PCR targeting a 208 nt
fragment of the CnNPHV NS3 gene (Table 4). Primers sequences
were deduced using Primer-Blast (Ye et al., 2012) from the initial
consensus sequence for NS3 obtained from three Population [A]
samples ampliﬁed using the nested PCR above. The PCR was
performed using 2x PCRBIO Ultra Mix kit (PCR BIOSYSTEMS) with
an initial denaturation at 95 1C for 2 min and 40 cycles of [95 1C for
15 s, 55 1C for 15 s and 72 1C for 30 s] followed by a ﬁnal
elongation at 72 1C for 2 min.
E1/E2 and 50UTR ampliﬁcation. A 962 bp region of the E1and E2
genes (spanning 868–1826 nt of canine hepacivirus isolate
AAK-2011 (Accession number JF744991)) and the 50UTR
(301 bp) were ampliﬁed by nested PCR using Amplitaq Gold
DNA polymerase (life Technologies), and primers described
elsewhere (Burbelo et al., 2012; Kapoor et al., 2011). The
primary round underwent initial denaturation for 8 min at
95 1C followed by 10 cycles of [95 1C for 40 s, 59 1C (0.5 1C/
cycle) for 45 s and 72 1C for 80 s] then 30 cycles of [95 1C for
30 s, 55 1C for 40 s and 72 1C for 80 s] and a ﬁnal elongation at
72 1C for 5 min. The secondary round was performed as
described for the primary round except the annealing tem-
perature for the ﬁrst 10 cycles was 65 1C (0.5 1C/cycle).
Detection of co-infection with canine infectious respiratory dis-
ease (CIRD) associated viruses. Respiratory samples were
screened for the presence of known CIRD viral pathogens as
described previously: canine herpes virus (HCV), canine
respiratory coronavirus (CRCoV) (Erles et al., 2003, 2004) and
canine pneumovirus (CnPnV) except 2 dogs (Mitchell et al.,
2013b).
(ii) Histopathology
Formalin-ﬁxed parafﬁn-embedded tissues sections were pro-
cessed and stained with haematoxylin and eosin. The histological
sections were examined, blind, by board-certiﬁed veterinary
pathologists (Population [A] by HB and Population [B] by SLP).
Population [A]. Multiple respiratory tissues were graded for several
features (neutrophils, lymphocytes, plasma cells, macrophage,
Table 4
Hepacivirus speciﬁc primer sequences for NS3 helicase gene.
Primer name Position Sequence (50-30)
NS3F1 Sense ACTTGCTACTGCTACGCCAC
NS3R1 Ani-sense AGCATTAGCTCCGGCCTTTC
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MALT reactivity, oedema, ﬁbrin and evidence of repair) from 0
(none or normal level), through to 3 (severely affected). An overall
grade (0–3) for the respiratory tract as a whole was determined
based on an assessment of all the changes taken together as
described previously (Mitchell et al., 2013b).
Population [B]. Tracheal, lung and liver tissues were each assigned
an overall histopathological score. For the trachea, a separate score
was assigned for cilia morphology as described previously
(Mitchell et al., 2013a). Brieﬂy, scores were based on the severity
and distribution of lesions, ranging from 0 (no signiﬁcant
histological abnormality recognised) to 4 (marked, extensive/
diffuse changes). Cilia were scored from 0 (dense, long cilia) to 4
(marked irregularity or diffuse cilia loss)
(iii) In situ hybridisation
Viral RNA was detected by in situ hybridisation using the
QuantiGenes ViewRNA ISH Tissue 2-Plex Assay kit (Panomics/
Affymetrix, Inc) according to the manufacturers' instruction. A
mixture of three Probes sets targeting CnNPHV genomic RNA
regions (nucleotides 840–2040, 3973–5010 and 7600–8634 of
Accession no. JQ434001) corresponding to the core/E1 and E2
envelopes, NS3 helicase/NS4a and NS5b (RdRp) genes were used
(Affymetrix). A Probe set for GAPDH RNA (Affymetrix, Accession
no. NM_001003142) was employed as a positive control. Formalin-
ﬁxed, parafﬁn-embedded (FFPE) tissues sections (5þ/1 μm)
were prepared on SuperFrost Plus slides. Sections were ﬁxed for
2 h at 60 1C, deparafﬁnised, dehydrated, and permeabilized before
the hybridisation steps and staining with Fast Red substrate (QG
ViewRNA Chromogenic Signal Ampliﬁcation kit (Panomics/Affy-
metrix, Inc.). The GAPDH positive control was detected with Fast
Blue substrate (Panomics/Affymetrix, Inc.). Stained tissue sections
were brieﬂy treated with Meyer's haematoxylin (Sigma/Aldrich,
UK) and dried before visualised by bright ﬁeld light microscopy at
40 magniﬁcation.
(iv) Statistical analysis of data
Data were recorded in excel spread sheets and imported into
IBM SPSS Statistics 22 for analysis. Associations between the
presence of CnNPHV in tissues and clinical respiratory score at
euthanasia, time in kennel, respiratory score, histology score and
year of collection were examined using Chi-square and Fisher's
exact tests with risk ratio calculator.
(v) DNA sequencing and phylogenetic analysis
PCR products were separated on an agarose gel and puriﬁed
using the Qiaquick gel extraction puriﬁcation kit (Qiagen) prior to
cloning and/or DNA sequencing. PCR amplicons from the NS3
(300–500 bp or 208 bp), E1/E2 (962 bp) and 50UTR (301 bp) were
cloned into the pT7blue2 blunt vector (Novagen, UK), pGEM-T Easy
vector (Promega, UK) or pCR2.1 TA cloning vector (Life Technol-
ogy) and sequenced (DNA Sequencing and Services, University of
Dundee, UK). A consensus sequence for each sample was gener-
ated from two or more clones, sequenced on both strands, using
Clustal Omega multiple sequence alignment after the deletion of
primers binding sites.
Nucleic acid similarity searches were performed using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast). Amino acid (a.a.) sequences
were deduced from the nt consensus sequences using EMBOSS
Tools at http://www.ebi.ac.uk/Tools/st/emboss_transeq/. Multiple
sequence alignments were performed and identity matrices
determined using OMEGA Clustal at http://www.ebi.ac.uk/Tools/
msa/clustalo/. Phylogenetic analysis was conducted using MEGA
version 6 (Tamura et al., 2013).
GenBank accession numbers
CnNPHV helicase, 50UTR and E1/E2 partial sequences used in
multiple sequence alignment and phylogenetics have been
assigned GenBank Accession numbers. NS3: KR349931-
KR349952. The 50UTR: KR349929 (5-T) and KR349930 (12-T), E1/
E2: KR349928 (42-T).
Published CnNPHV, NPHV and HCV sequences used in this
study and their accession numbers are listed below:
AK-2012 isolate NZP-1: (JQ434001), AK-2012 isolate NPHV-G1-073:
(JQ434002), AK-2012 isolate NPHV-A6-006: (JQ434003), AK-2012 iso-
late NPHV-B10-022 (JQ434004), AK-2012 isolate NPHV-F8–068
(JQ434005), AK-2012 isolate NPHV-G5-077: (JQ434006), AK-2012 iso-
late NPHV-H10-094: (JQ434007), AK-2012 isolate NPHV-H3-011:
(JQ434008), SMKL-2012 isolate NPHV_EF369_98: (JX948116), SMKL-
2012 isolate NPHV_EF3317_98 (JX948117), SMKL isolate NPHV_
EF319_98: (JX948118), SMKL-2012 isolate NPHV_EF330_97
(JX948120), SMKL isolate EF319_97: (JX948121), AAK-2011: (JF744-
991), AAK-2011 isolate CHV- K217: (JF744992), AAK-2011 isolate CHV-
K188: (JF744993), AAK-2011 isolate CHV- K180: (JF744994), AAK-2011
isolate CHV- K154: (JF744995), AAK-2011 isolate CHV- K136:
(JF744996), CHV: (JQ181558), Eq179/GER/2012 (KC411810), Eq285/
GER/2012 (KC411811), AS9218 (KJ469459), AS9330 (KJ469466), horse/
DH1/HUN/2013 (KF177391), Bat-PDB-491 (KC796078) HCV- subtype
1a: (M62321).
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